Dementia and Alzheimer's Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

The Dementia and Alzheimer’s Disease Treatment Market was valued at USD 12.17 Billion in 2024, and is expected to reach USD 17.62 Billion by 2030, rising at a CAGR of 6.56%. As global populations age, the prevalence of Alzheimer’s disease and related dementias is rising significantly, fueling demand for more effective therapeutic interventions. While the market has traditionally been driven by symptomatic treatments such as cholinesterase inhibitors and NMDA receptor antagonists, new advancements in neuroscience are now paving the way for disease-modifying therapies. These newer approaches aim to address the biological mechanisms of the disease, including beta-amyloid plaques and tau protein tangles. Pharmaceutical companies and research institutions are investing heavily in this direction. Despite the progress, the field faces ongoing hurdles due to the complexity of the disease and the high rate of failure in clinical trials, which continue to challenge drug development and commercialization efforts.

Key Market Drivers

Growth in Healthcare Industry

The continued expansion of the global healthcare industry - generating more than USD 4 trillion in annual revenues - serves as a major catalyst for growth in the dementia and Alzheimer’s treatment market. Key contributors include pharmaceuticals and biotechnology, which together account for nearly USD 850 billion, and diagnostics and medical technology, generating over USD 400 billion. With improved life expectancy and better access to medical services, healthcare systems are increasingly prioritizing age-related neurodegenerative diseases. This trend is driving investment in research and development focused on Alzheimer’s and dementia therapies, and is supported by growing global awareness and demand for effective long-term treatment options.

Key Market Challenges

High Cost of Treatment and Care

The elevated cost of treatment and associated care services represents a key barrier in the dementia and Alzheimer’s disease treatment market. The financial strain extends beyond pharmaceutical expenditures, encompassing long-term care, specialized nursing, and daily assistance - all of which are typically not fully covered by public health insurance in many regions. The introduction of innovative disease-modifying therapies, while clinically promising, adds to cost concerns due to their complex production, monitoring requirements, and regulatory demands. These high costs challenge the affordability and accessibility of new treatments, particularly in low- and middle-income countries with constrained healthcare budgets and limited infrastructure for administering advanced therapeutics.

Key Market Trends

Advancement in Tau-Targeted Therapies

An important trend shaping the market is the increasing focus on tau-targeted therapies as an alternative or complement to amyloid-focused treatments. Research has shown that abnormal accumulation of tau proteins, which form neurofibrillary tangles in the brain, is closely associated with cognitive decline in Alzheimer’s patients. As traditional therapies targeting amyloid plaques have delivered limited results, pharmaceutical companies are shifting attention toward tau as a therapeutic target. Innovations such as ACI-35 - a liposome-based vaccine targeting phosphorylated tau - have shown promising safety and tolerability profiles in clinical trials. The pipeline now includes various modalities like monoclonal antibodies, antisense oligonucleotides, and small molecule inhibitors aimed at mitigating tau pathology. These advancements are expected to drive future breakthroughs in disease-modifying treatments.

Key Market Players

• Merz Pharma GmbH & Co. KGaA
• Novartis AG
• Pfizer, Inc.
• Ono Pharmaceutical Co., Ltd.
• Johnson & Johnson Services, Inc.
• H. Lundbeck A/S
• F. Hoffmann-La Roche Ltd.
• AbbVie Inc.
• Eli Lilly and Company
• Corium, Inc.

Report Scope

In this report, the Global Dementia and Alzheimer’s Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dementia and Alzheimer’s Disease Treatment Market, By Drug Class:

• Cholinergic/ Cholinesterase (ChE) Inhibitors
• Memantine
• Combination Drugs
• Others

Dementia and Alzheimer’s Disease Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Dementia and Alzheimer’s Disease Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dementia and Alzheimer’s Disease Treatment Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.